American Gastroenterological Association Institute technical review on prevention and treatment of hepatitis b virus reactivation during immunosuppressive drug therapy

Gastroenterology

Volumn 148, Issue 1, 2015, Pages 221-244.e3

  Perrillo, Robert P ^a   Gish, Robert ^b,c   Falck Ytter, Yngve T ^d  

^a BAYLOR UNIVERSITY MEDICAL CENTER   (United States)

^b STANFORD UNIVERSITY   (United States)

^c HEPATITIS B FOUNDATION   (United States)

^d CASE WESTERN RESERVE UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ABATACEPT; ANTIVIRUS AGENT; AZATHIOPRINE; BIOLOGICAL PRODUCT; CORTICOSTEROID; GLUCOCORTICOID; IMMUNOSUPPRESSIVE AGENT; INFLIXIMAB; MERCAPTOPURINE; METHOTREXATE; OFATUMUMAB; PROTEIN TYROSINE KINASE INHIBITOR; RITUXIMAB; BIOLOGICAL MARKER; HEPATITIS B ANTIBODY; HEPATITIS B SURFACE ANTIGEN; VIRUS DNA;

ANTIVIRAL THERAPY; ARTICLE; BREAST CANCER; HEMATOPOIETIC STEM CELL TRANSPLANTATION; HEPATITIS B; HUMAN; IMMUNOSUPPRESSIVE TREATMENT; LIVER CELL CARCINOMA; LIVER TRANSPLANTATION; NONHODGKIN LYMPHOMA; PRIORITY JOURNAL; PROPHYLAXIS; RISK FACTOR; SCREENING; VIRUS REACTIVATION; VIRUS REPLICATION; BLOOD; DRUG EFFECTS; GASTROENTEROLOGY; GENETICS; HEPATITIS B VIRUS; IMMUNOLOGY; MEDICAL SOCIETY; META ANALYSIS; PATHOGENICITY; RECURRENT DISEASE; TREATMENT OUTCOME; VIROLOGY; VIRUS ACTIVATION; VIRUS LOAD;

ANTIVIRAL AGENTS; BIOLOGICAL MARKERS; DNA, VIRAL; GASTROENTEROLOGY; HEPATITIS B; HEPATITIS B ANTIBODIES; HEPATITIS B SURFACE ANTIGENS; HEPATITIS B VIRUS; HUMANS; IMMUNOSUPPRESSIVE AGENTS; RECURRENCE; RISK FACTORS; SOCIETIES, MEDICAL; TREATMENT OUTCOME; VIRAL LOAD; VIRUS ACTIVATION;

EID: 84922858375     PISSN: 00165085     EISSN: 15280012     Source Type: Journal    
DOI: 10.1053/j.gastro.2014.10.038     Document Type: Article

References (106)

1. J.H. Hoofnagle Reactivation of hepatitis B Hepatology 49 2009 S156 S165
2. R.M. Galbraith, A.L. Eddleston, and R. Williams Fulminant hepatic failure in leukaemia and choriocarcinoma related to withdrawal of cytotoxic drug therapy Lancet 2 1975 528 530
3. J. Nagington Reactivation of hepatitis B after transplantation operations Lancet 1 1977 558 560
4. R.P. Perrillo Acute flares in chronic hepatitis B: the natural and unnatural history of an immunologically mediated liver disease Gastroenterology 120 2001 1009 1022
5. W. Yeo, B. Zee, and S. Zhong Comprehensive analysis of risk factors associating with Hepatitis B virus (HBV) reactivation in cancer patients undergoing cytotoxic chemotherapy Br J Cancer 90 2004 1306 1311
6. D. Shouval, and O. Shibolet Immunosuppression and HBV reactivation Semin Liver Dis 33 2013 167 177
7. R. Perez-Alvarez, C. Diaz-Lagares, and F. Garcia-Hernandez Hepatitis B virus (HBV) reactivation in patients receiving tumor necrosis factor (TNF)-targeted therapy: analysis of 257 cases Medicine (Baltimore) 90 2011 359 371
8. H.J. Dong, L.N. Ni, and G.F. Sheng Risk of hepatitis B virus (HBV) reactivation in non-Hodgkin lymphoma patients receiving rituximab-chemotherapy: a meta-analysis J Clin Virol 57 2013 209 214
9. Rituxan package brochure. Available at: http://druginserts.com/lib/rx/meds/rituxan-1/. Accessed November 17, 2014.
10. S. Pol, and P. Lampertico First-line treatment of chronic hepatitis B with entecavir or tenofovir in 'real-life' settings: from clinical trials to clinical practice J Viral Hepat 19 2012 377 386
11. C.M. Weinbaum, I. Williams, and E.E. Mast Recommendations for identification and public health management of persons with chronic hepatitis B virus infection MMWR Recomm Rep 57 2008 1 20
12. A.S. Lok, and B.J. McMahon Chronic hepatitis B: update 2009 Hepatology 50 2009 661 662
13. EASL clinical practice guidelines: management of chronic hepatitis B virus infection J Hepatol 57 2012 167 185
14. Y.F. Liaw, J.H. Kao, and T. Piratvisuth Asia-Pacific consensus statement on the management of chronic hepatitis B: a 2012 update Hepatol Int 6 2012 531 561
15. A.S. Artz, M.R. Somerfield, and J.J. Feld American Society of Clinical Oncology provisional clinical opinion: chronic hepatitis B virus infection screening in patients receiving cytotoxic chemotherapy for treatment of malignant diseases J Clin Oncol 28 2010 3199 3202
16. J.P. Hwang, M.J. Fisch, and H. Zhang Low rates of hepatitis B virus screening at the onset of chemotherapy J Oncol Pract 8 2012 e32 e39
17. J.G. Stine, M. Bass, and D. Ibrahim Dermatologists' awareness of and screening practices for hepatitis B virus infection before initiating tumor necrosis factor-alpha inhibitor therapy South Med J 104 2011 781 788
18. J.G. Stine, O.S. Khokhar, and J. Charalambopoulos Rheumatologists' awareness of and screening practices for hepatitis B virus infection prior to initiating immunomodulatory therapy Arthritis Care Res (Hoboken) 62 2010 704 711
19. L.B. Cohen, R.M. Nanau, and F. Delzor Biologic therapies in inflammatory bowel disease Transl Res 163 2014 533 556
20. S. Sultan, Y. Falck-Ytter, and J.M. Inadomi The AGA institute process for developing clinical practice guidelines part one: grading the evidence Clin Gastroenterol Hepatol 11 2013 329 332
21. K.R. Reddy, K.L. Beavers, and S.P. Hammond American Gastroenterological Association Institute guideline on the prevention and treatment of hepatitis B virus reactivation during immunosuppressive drug therapy Gastroenterology 148 2015 215 219
22. G.H. Guyatt, A.D. Oxman, and G.E. Vist GRADE: an emerging consensus on rating quality of evidence and strength of recommendations BMJ 336 2008 924 926
23. GRADEpro software. 2009. http://gradeworkinggroup.org/.
24. Review Manager (RevMan). Version 5.2 2012 The Nordic Cochrane Centre, The Cochrane Collaboration Copenhagen
25. C. Hsu, C.A. Hsiung, and I.J. Su A revisit of prophylactic lamivudine for chemotherapy-associated hepatitis B reactivation in non-Hodgkin's lymphoma: a randomized trial Hepatology 47 2008 844 853
26. Y.H. Huang, L.T. Hsiao, and Y.C. Hong Randomized controlled trial of entecavir prophylaxis for rituximab-associated hepatitis B virus reactivation in patients with lymphoma and resolved hepatitis B J Clin Oncol 31 2013 2765 2772
27. J.W. Jang, J.Y. Choi, and S.H. Bae A randomized controlled study of preemptive lamivudine in patients receiving transarterial chemo-lipiodolization Hepatology 43 2006 233 240
28. G.K. Lau, H.H. Yiu, and D.Y. Fong Early is superior to deferred preemptive lamivudine therapy for hepatitis B patients undergoing chemotherapy Gastroenterology 125 2003 1742 1749
29. M. Long, W. Jia, and S. Li A single-center, prospective and randomized controlled study: Can the prophylactic use of lamivudine prevent hepatitis B virus reactivation in hepatitis B s-antigen seropositive breast cancer patients during chemotherapy? Breast Cancer Res Treat 127 2011 705 712
30. OpenMeta[Analyst]. Version 3.17.14. 2014. http://www.cebm.brown.edu/open-meta.
31. I. Tiede, G. Fritz, and S. Strand CD28-dependent Rac1 activation is the molecular target of azathioprine in primary human CD4+ T lymphocytes J Clin Invest 111 2003 1133 1145
32. E. Sagnelli, G. Manzillo, and G. Maio Serum levels of hepatitis B surface and core antigens during immunosuppressive treatment of HBsAg-positive chronic active hepatitis Lancet 2 1980 395 397
33. M.A. Flowers, J. Heathcote, and I.R. Wanless Fulminant hepatitis as a consequence of reactivation of hepatitis B virus infection after discontinuation of low-dose methotrexate therapy Ann Intern Med 112 1990 381 382
34. A. Tamori, T. Koike, and H. Goto Prospective study of reactivation of hepatitis B virus in patients with rheumatoid arthritis who received immunosuppressive therapy: evaluation of both HBsAg-positive and HBsAg-negative cohorts J Gastroenterol 46 2011 556 564
35. H. Hagiyama, T. Kubota, and Y. Komano Fulminant hepatitis in an asymptomatic chronic carrier of hepatitis B virus mutant after withdrawal of low-dose methotrexate therapy for rheumatoid arthritis Clin Exp Rheumatol 22 2004 375 376
36. S.W. Schalm, W.H. Summerskill, and G.L. Gitnick Contrasting features and responses to treatment of severe chronic active liver disease with and without hepatitis B S antigen Gut 17 1976 781 786
37. K.C. Lam, C.L. Lai, and C. Trepo Deleterious effect of prednisolone in HBsAg-positive chronic active hepatitis N Engl J Med 304 1981 380 386
38. R. Tur-Kaspa, Y. Shaul, and D.D. Moore The glucocorticoid receptor recognizes a specific nucleotide sequence in hepatitis B virus DNA causing increased activity of the HBV enhancer Virology 167 1988 630 633
39. G.H. Scullard, C.I. Smith, and T.C. Merigan Effects of immunosuppressive therapy on viral markers in chronic active hepatitis B Gastroenterology 81 1981 987 991
40. J.H. Hoofnagle, G.L. Davis, and S.C. Pappas A short course of prednisolone in chronic type B hepatitis. report of a randomized, double-blind, placebo-controlled trial Ann Intern Med 104 1986 12 17
41. R.P. Perrillo, E.R. Schiff, and G.L. Davis A randomized, controlled trial of interferon alfa-2b alone and after prednisone withdrawal for the treatment of chronic hepatitis B. The Hepatitis Interventional Therapy Group N Engl J Med 323 1990 295 301
42. Y.F. Liaw, S.L. Tsai, and R.N. Chien Prednisolone priming enhances Th1 response and efficacy of subsequent lamivudine therapy in patients with chronic hepatitis B Hepatology 32 2000 604 609
43. T.W. Kim, M.N. Kim, and J.W. Kwon Risk of hepatitis B virus reactivation in patients with asthma or chronic obstructive pulmonary disease treated with corticosteroids Respirology 15 2010 1092 1097
44. A.L. Cheng, C.A. Hsiung, and I.J. Su Steroid-free chemotherapy decreases risk of hepatitis B virus (HBV) reactivation in HBV-carriers with lymphoma Hepatology 37 2003 1320 1328
45. G.S. Habib Systemic effects of intra-articular corticosteroids Clin Rheumatol 28 2009 749 756
46. D. Tracey, L. Klareskog, and E.H. Sasso Tumor necrosis factor antagonist mechanisms of action: a comprehensive review Pharmacol Ther 117 2008 244 279
47. A. Papa, C. Felice, and M. Marzo Prevalence and natural history of hepatitis B and C infections in a large population of IBD patients treated with anti-tumor necrosis factor-alpha agents J Crohns Colitis 7 2013 113 119
48. C. Charpin, S. Guis, and P. Colson Safety of TNF-blocking agents in rheumatic patients with serology suggesting past hepatitis B state: results from a cohort of 21 patients Arthritis Res Ther 11 2009 R179
49. S. Mori Past hepatitis B virus infection in rheumatoid arthritis patients receiving biological and/or nonbiological disease-modifying antirheumatic drugs Mod Rheumatol 21 2011 621 627
50. M.B. Carroll, and M.A. Forgione Use of tumor necrosis factor alpha inhibitors in hepatitis B surface antigen-positive patients: a literature review and potential mechanisms of action Clin Rheumatol 29 2010 1021 1029
51. Remicade. 2014. https://www.remicade.com/remicade/global/index.html.
52. A. Abramson, A. Menter, and R. Perrillo Psoriasis, hepatitis B, and the tumor necrosis factor-alpha inhibitory agents: a review and recommendations for management J Am Acad Dermatol 67 2012 1349 1361
53. G. Germanidis, P. Hytiroglou, and M. Zakalka Reactivation of occult hepatitis B virus infection, following treatment of refractory rheumatoid arthritis with abatacept J Hepatol 56 2012 1420 1421
54. P.S. Kim, G.Y. Ho, and P.E. Prete Safety and efficacy of abatacept in eight rheumatoid arthritis patients with chronic hepatitis B Arthritis Care Res (Hoboken) 64 2012 1265 1268
55. K. Ikeda, Y. Shiga, and A. Takahashi Fatal hepatitis B virus reactivation in a chronic myeloid leukemia patient during imatinib mesylate treatment Leuk Lymphoma 47 2006 155 157
56. B.W. Kang, S.J. Lee, and J.H. Moon Chronic myeloid leukemia patient manifesting fatal hepatitis B virus reactivation during treatment with imatinib rescued by liver transplantation: case report and literature review Int J Hematol 90 2009 383 387
57. G.M. Lai, S.L. Yan, and C.S. Chang Hepatitis B reactivation in chronic myeloid leukemia patients receiving tyrosine kinase inhibitor World J Gastroenterol 19 2013 1318 1321
58. R. Navarro, E. Vilarrasa, and P. Herranz Safety and effectiveness of ustekinumab and antitumour necrosis factor therapy in patients with psoriasis and chronic viral hepatitis B or C: a retrospective, multicentre study in a clinical setting Br J Dermatol 168 2013 609 616
59. H.Y. Chiu, C.H. Chen, and M.S. Wu The safety profile of ustekinumab in the treatment of patients with psoriasis and concurrent hepatitis B or C Br J Dermatol 169 2013 1295 1303
60. S.N. Pei, M.C. Ma, and M.C. Wang Analysis of hepatitis B surface antibody titers in B cell lymphoma patients after rituximab therapy Ann Hematol 91 2012 1007 1012
61. Nayernama A, Waldron P, Rand M, et al. Hepatitis B virus reactivation in CD20 antibody-treated patients: evaluation of post market data from the FDA adverse event reporting system. Presented at: Proceedings from AASLD/NIH Emerging Trends Conference on HBV Reactivation; March 21, 2013; Crystal City, VA; pp 105-106.
62. W. Yeo, T.C. Chan, and N.W. Leung Hepatitis B virus reactivation in lymphoma patients with prior resolved hepatitis B undergoing anticancer therapy with or without rituximab J Clin Oncol 27 2009 605 611
63. S.N. Pei, C.H. Chen, and C.M. Lee Reactivation of hepatitis B virus following rituximab-based regimens: a serious complication in both HBsAg-positive and HBsAg-negative patients Ann Hematol 89 2010 255 262
64. M. Mitka FDA: Increased HBV reactivation risk with ofatumumab or rituximab JAMA 310 2013 1664
65. J. Sperl, S. Frankova, and E. Kieslichova Urgent liver transplantation for chemotherapy-induced HBV reactivation: a suitable option in patients recently treated for malignant lymphoma Transplant Proc 45 2013 2834 2837
66. M.J. Oh, and H.J. Lee A study of hepatitis B virus reactivation associated with rituximab therapy in real-world clinical practice: a single-center experience Clin Mol Hepatol 19 2013 51 59
67. W.I. Cheung, S.Y. Lin, and V.K. Leung Prospective evaluation of seropositive occult hepatitis B viral infection in lymphoma patients receiving chemotherapy Hong Kong Med J 17 2011 376 380
68. C. Hsu, H.H. Tsou, and S.J. Lin Chemotherapy-induced hepatitis B reactivation in lymphoma patients with resolved HBV infection: a prospective study Hepatology 59 2014 2092 2100
69. Y.X. Koo, M. Tay, and Y.E. Teh Risk of hepatitis B virus (HBV) reactivation in hepatitis B surface antigen negative/hepatitis B core antibody positive patients receiving rituximab-containing combination chemotherapy without routine antiviral prophylaxis Ann Hematol 90 2011 1219 1223
70. K. Matsue, S. Kimura, and Y. Takanashi Reactivation of hepatitis B virus after rituximab-containing treatment in patients with CD20-positive B-cell lymphoma Cancer 116 2010 4769 4776
71. C.A. Liao, C.M. Lee, and H.C. Wu Lamivudine for the treatment of hepatitis B virus reactivation following chemotherapy for non-Hodgkin's lymphoma Br J Haematol 116 2002 166 169
72. A.S. Lok, R.H. Liang, and E.K. Chiu Reactivation of hepatitis B virus replication in patients receiving cytotoxic therapy. Report of a prospective study Gastroenterology 100 1991 182 188
73. H.J. Lee, D.Y. Kim, and B. Keam Lamivudine prophylaxis for hepatitis B virus carrier patients with breast cancer during adjuvant chemotherapy Breast Cancer 21 2014 387 393
74. W. Yeo, P.K. Chan, and P. Hui Hepatitis B virus reactivation in breast cancer patients receiving cytotoxic chemotherapy: a prospective study J Med Virol 70 2003 553 561
75. J. Lammer, K. Malagari, and T. Vogl Prospective randomized study of doxorubicin-eluting-bead embolization in the treatment of hepatocellular carcinoma: results of the PRECISION V study Cardiovasc Intervent Radiol 33 2010 41 52
76. X.M. Lao, G. Luo, and L.T. Ye Effects of antiviral therapy on hepatitis B virus reactivation and liver function after resection or chemoembolization for hepatocellular carcinoma Liver Int 33 2013 595 604
77. J.W. Jang, J.H. Kwon, and C.R. You Risk of HBV reactivation according to viral status and treatment intensity in patients with hepatocellular carcinoma Antivir Ther 16 2011 969 977
78. J.W. Park, K.W. Park, and S.H. Cho Risk of hepatitis B exacerbation is low after transcatheter arterial chemoembolization therapy for patients with HBV-related hepatocellular carcinoma: report of a prospective study Am J Gastroenterol 100 2005 2194 2200
79. W. Yeo, K.C. Lam, and B. Zee Hepatitis B reactivation in patients with hepatocellular carcinoma undergoing systemic chemotherapy Ann Oncol 15 2004 1661 1666
80. J. Tan, J. Zhou, and P. Zhao Prospective study of HBV reactivation risk in rheumatoid arthritis patients who received conventional disease-modifying antirheumatic drugs Clin Rheumatol 31 2012 1169 1175
81. J.W. Peng, G.N. Lin, and J.J. Xiao Hepatitis B virus reactivation in hepatocellular carcinoma patients undergoing transcatheter arterial chemoembolization therapy Asia Pac J Clin Oncol 8 2012 356 361
82. R. Caporali, F. Bobbio-Pallavicini, and F. Atzeni Safety of tumor necrosis factor alpha blockers in hepatitis B virus occult carriers (hepatitis B surface antigen negative/anti-hepatitis B core antigen positive) with rheumatic diseases Arthritis Care Res (Hoboken) 62 2010 749 754
83. R. Loomba, A. Rowley, and R. Wesley Systematic review: the effect of preventive lamivudine on hepatitis B reactivation during chemotherapy Ann Intern Med 148 2008 519 528
84. A.S. Lok, C.L. Lai, and N. Leung Long-term safety of lamivudine treatment in patients with chronic hepatitis B Gastroenterology 125 2003 1714 1722
85. F.W. Chen, L. Coyle, and B.E. Jones Entecavir versus lamivudine for hepatitis B prophylaxis in patients with haematological disease Liver Int 33 2013 1203 1210
86. H. Huang, X.Y. Li, and H.R. Li Preventing hepatitis B reactivation in HBsAg-positive patients with untreated diffuse large B-cell lymphoma with R-CHOP chemotherapy: a prospective study to compare entecavir and lamivudine J Clin Oncol 31 suppl 2013 abstr 8503
87. H. Kojima, H. Tsujimura, and T. Sugawara Prospective study of hepatitis B virus reactivation in HBsAg-negative patients after chemotherapy with rituximab: HBV-DNA monitoring and entecavir prophylaxis J Hepatol 56 2012 S206 (abstract)
88. H.R. Li, J.J. Huang, and H.Q. Guo Comparison of entecavir and lamivudine in preventing hepatitis B reactivation in lymphoma patients during chemotherapy J Viral Hepat 18 2011 877 883
89. S.J. Kim, C. Hsu, and Y.Q. Song Hepatitis B virus reactivation in B-cell lymphoma patients treated with rituximab: analysis from the Asia Lymphoma Study Group Eur J Cancer 49 2013 3486 3496
90. C.L. Lai, D. Shouval, and A.S. Lok Entecavir versus lamivudine for patients with HBeAg-negative chronic hepatitis B N Engl J Med 354 2006 1011 1020
91. T.T. Chang, R.G. Gish, and R. de Man A comparison of entecavir and lamivudine for HBeAg-positive chronic hepatitis B N Engl J Med 354 2006 1001 1010
92. S. Yu, H. Jianqin, and W. Wei The efficacy and safety of nucleos(t)ide analogues in the treatment of HBV-related acute-on-chronic liver failure: a meta-analysis Ann Hepatol 12 2013 364 372
93. K.M. Kitrinos, A. Corsa, and Y. Liu No detectable resistance to tenofovir disoproxil fumarate after 6 years of therapy in patients with chronic hepatitis B Hepatology 59 2014 434 442
94. U. Zurawska, L.K. Hicks, and G. Woo Hepatitis B virus screening before chemotherapy for lymphoma: a cost-effectiveness analysis J Clin Oncol 30 2012 3167 3173
95. F.L. Day, J. Karnon, and D. Rischin Cost-effectiveness of universal hepatitis B virus screening in patients beginning chemotherapy for solid tumors J Clin Oncol 29 2011 3270 3277
96. M.L. LeFevre Screening for hepatitis B virus infection in nonpregnant adolescents and adults: U.S. Preventive Services Task Force Recommendation Statement Ann Intern Med 161 2014 58 66
97. R. Chou, T. Dana, and C. Bougatsos Screening for hepatitis B virus infection in adolescents and adults: a systematic review to update the U.S. Preventive Services Task Force recommendation Ann Intern Med 161 2014 31 45
98. Hoofnagle JH. Reactivation of hepatitis B: definition and terminology. Presented at: Proceedings from AASLD/NIH Emerging Trends Conference on HBV Reactivation; March 21, 2013; Crystal City, VA; pp 17-20.
99. J.P. Hwang, A. Barbo, and R. Perrillo Hepatitis B reactivation during cancer chemotherapy: an international survey of the membership of the American Association for the Study of Liver Diseases J Viral Hepat 2014 Sep 15 [Epub ahead of print]
100. W. Yeo, W.M. Ho, and P. Hui Use of lamivudine to prevent hepatitis B virus reactivation during chemotherapy in breast cancer patients Breast Cancer Res Treat 88 2004 209 215
101. C. Loras, C. Saro, and F. Gonzalez-Huix Prevalence and factors related to hepatitis B and C in inflammatory bowel disease patients in Spain: a nationwide, multicenter study Am J Gastroenterol 104 2009 57 63
102. M.E. Altunoz, E. Senates, and A. Yesil Patients with inflammatory bowel disease have a lower response rate to HBV vaccination compared to controls Dig Dis Sci 57 2012 1039 1044
103. A. Liu, L. Zhang, and J. Cheng Comparison of the efficacy of entecavir and lamivudine in the treatment of chronic hepatitis B: a meta-analysis Afr J Biotechnol 10 2011 8131 8136
104. G. Woo, G. Tomlinson, and Y. Nishikawa Tenofovir and entecavir are the most effective antiviral agents for chronic hepatitis B: a systematic review and Bayesian meta-analyses Gastroenterology 139 2010 1218 1229
105. J. Petersen, and M. Buti Considerations for the long-term treatment of chronic hepatitis B with nucleos(t)ide analogs Expert Rev Gastroenterol Hepatol 6 2012 683 693 quiz 694
106. T.T. Chang, C.L. Lai, and S. Kew Yoon Entecavir treatment for up to 5 years in patients with hepatitis B e antigen-positive chronic hepatitis B Hepatology 51 2010 422 430